Risk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ

Cette étude analyse le risque de carcinome épidermoïde du sein après une reconstruction par implant pour un cancer du sein non épidermoïde

Résumé en anglais

The US Food and Drug Administration issued a safety communication on September 8, 2022, about reports of squamous cell carcinoma (SCC) and various lymphomas of the breast associated with breast implants. These malignant tumors were distinct from breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), which is the subject of a black box warning on all saline- and silicone gel–filled breast implants since 2020. While BIA-ALCL has been almost exclusively associated with textured implants, SCC has been reported with both smooth and textured implants. The incidence of BIA-ALCL has been increasing; however, there are no population-based estimates of the incidence rate of breast SCC after implant-based reconstruction. We report on the incidence rate and relative risk of breast SCC after implant reconstruction after mastectomy for breast non-SCC and carcinoma in situ.